Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018

Los PROA (Programa de Optimización de antimicrobianos) tienen como finalidad evaluar y fortalecer el uso apropiado de antimicrobianos (AB), por medio del conocimiento y educación para seleccionar el régimen óptimo que brinde mejores desenlaces clínicos, menos eventos adversos, llevar a metas de cont...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2024
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
spa
OAI Identifier:
oai:repository.urosario.edu.co:10336/43229
Acceso en línea:
https://repository.urosario.edu.co/handle/10336/43229
Palabra clave:
Proa
Programa de optimización de antimicrobianos
Antibiótico
Antimicrobiano
Desescalamiento
Optimización
Antimicrobial
Antibiotics
Stewardship
De escalation
Rights
License
Attribution-NonCommercial-ShareAlike 4.0 International
id EDOCUR2_6c874af86d15b676d8be90cca373fb12
oai_identifier_str oai:repository.urosario.edu.co:10336/43229
network_acronym_str EDOCUR2
network_name_str Repositorio EdocUR - U. Rosario
repository_id_str
dc.title.none.fl_str_mv Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
dc.title.TranslatedTitle.none.fl_str_mv Characterization of an antimicrobial stewardship program in a level IV hospital institution in Bogotá Colombia between 2015 2018
title Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
spellingShingle Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
Proa
Programa de optimización de antimicrobianos
Antibiótico
Antimicrobiano
Desescalamiento
Optimización
Antimicrobial
Antibiotics
Stewardship
De escalation
title_short Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
title_full Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
title_fullStr Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
title_full_unstemmed Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
title_sort Caracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018
dc.contributor.advisor.none.fl_str_mv Pérez Franco, Jairo Enrique
Cruz Reyes, Danna Lesley
López, María José
dc.subject.none.fl_str_mv Proa
Programa de optimización de antimicrobianos
Antibiótico
Antimicrobiano
Desescalamiento
Optimización
topic Proa
Programa de optimización de antimicrobianos
Antibiótico
Antimicrobiano
Desescalamiento
Optimización
Antimicrobial
Antibiotics
Stewardship
De escalation
dc.subject.keyword.none.fl_str_mv Antimicrobial
Antibiotics
Stewardship
De escalation
description Los PROA (Programa de Optimización de antimicrobianos) tienen como finalidad evaluar y fortalecer el uso apropiado de antimicrobianos (AB), por medio del conocimiento y educación para seleccionar el régimen óptimo que brinde mejores desenlaces clínicos, menos eventos adversos, llevar a metas de control de infecciones intrahospitalarias, menores tasas de resistencia a AB y reducir costos en salud. Es importante generar estudios epidemiológicos que aporten datos de las intervenciones en los PROA y así evaluar su desempeño. Objetivos: Describir las principales características clínicas y terapéuticas de un programa de optimización de tratamiento antimicrobiano en pacientes atendidos por diferentes servicios médicos y con patologías infecciosas en una institución de salud de IV nivel de Bogotá – Colombia. Métodos: Estudio observacional, descriptivo y de corte transversal. Datos retrospectivos obtenidos de los registros originales del PROA. Recopilación de datos se para los años 2015 al 2018. La población estuvo compuesta por pacientes mayores de 18 años hospitalizados por patologías infecciosas que requirieron tratamiento AB. Resultados: Se obtuvieron datos de las historias clínicas de 10.886 pacientes de los que se analizaron 9379. La edad promedio 65.5 años (desviación estándar (DE) 18,1 años) , y 4964 (53,1%) mujeres. El diagnóstico más frecuente fue infección de vías urinarias (IVU) 21%, seguido de neumonía/empiema 15.4%. El 81,1% de las prescripciones son consideradas bien formuladas. Piperacilina tazobactam el AB más frecuentemente formulado 41%. Se describe 15.6% de sospecha de infecciones asociadas a la atención en salud (IAAS). El tiempo en promedio hasta el desescalamiento AB no superó 3.1 días (DE=2,2 días). El porcentaje de intervenciones por infectología (modificación o suspensión de terapia) estuvo entre 53,5% y 59.7% durante los años del estudio. Hubo una reducción en el promedio de los días programados de tratamiento por los años del estudio, 2016: 11 días en contraste con 2018: 6 días. Conclusiones: Las infecciones más frecuentes que implican atención hospitalaria y prescripción de AB son: infección de vías urinarias (IVU), neumonía/empiemas, Apendicitis/peritonitis/absceso intraabdominal, Choque séptico/sepsis de foco a esclarecer. Los AB más frecuentemente prescritos para estas infecciones son: piperacilina tazobactam, vancomicina, meropenem, ertapenem y ceftriaxona. Un porcentaje significativo de los pacientes con AB tuvieron formulaciones acertadas, y aún en estos casos la prescripción se puede optimizar. La optimización se puede hacer con base en guías de manejo o de realización y análisis de reportes microbiológicos por un programa PROA.
publishDate 2024
dc.date.accessioned.none.fl_str_mv 2024-08-06T18:11:27Z
dc.date.available.none.fl_str_mv 2024-08-06T18:11:27Z
dc.date.created.none.fl_str_mv 2024-08-01
dc.date.embargoEnd.none.fl_str_mv info:eu-repo/date/embargoEnd/2025-08-08
dc.type.none.fl_str_mv bachelorThesis
dc.type.coar.fl_str_mv http://purl.org/coar/resource_type/c_7a1f
dc.type.document.none.fl_str_mv Trabajo de grado
dc.type.spa.none.fl_str_mv Trabajo de grado
dc.identifier.uri.none.fl_str_mv https://repository.urosario.edu.co/handle/10336/43229
url https://repository.urosario.edu.co/handle/10336/43229
dc.language.iso.none.fl_str_mv spa
language spa
dc.rights.*.fl_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
dc.rights.coar.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.rights.acceso.none.fl_str_mv Abierto (Texto Completo)
dc.rights.uri.*.fl_str_mv http://creativecommons.org/licenses/by-nc-sa/4.0/
rights_invalid_str_mv Attribution-NonCommercial-ShareAlike 4.0 International
Abierto (Texto Completo)
http://creativecommons.org/licenses/by-nc-sa/4.0/
http://purl.org/coar/access_right/c_abf2
dc.format.extent.none.fl_str_mv 86 PP
dc.format.mimetype.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidad del Rosario
dc.publisher.department.none.fl_str_mv Escuela de Medicina y Ciencias de la Salud
dc.publisher.program.none.fl_str_mv Especialización en Infectología
publisher.none.fl_str_mv Universidad del Rosario
institution Universidad del Rosario
dc.source.bibliographicCitation.none.fl_str_mv Spellberg, B. (121). Mandell, Douglas, Bennett. Enfermedades infecciosas. Principios y práctica (Novena ed., Vol. I, pp. 211-221). Elsevier España
Uddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., Hossain, M. J., & Koirala, N. (2021). Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of Infection and Public Health, 14(12), 1750–1766. https://doi.org/10.1016/j.jiph.2021.10.020
Huijbers, P. M. C., Blaak, H., de Jong, M. C. M., Graat, E. A. M., Vandenbroucke-Grauls, C. M. J. E., & de Roda Husman, A. M. (2015). Role of the environment in the transmission of antimicrobial resistance to humans: A review. Environmental Science & Technology, 49(20), 11993–12004. https://doi.org/10.1021/acs.est.5b02566
Machowska, A., & Stålsby Lundborg, C. (2018). Drivers of irrational use of antibiotics in Europe. International Journal of Environmental Research and Public Health, 16(1), 27. https://doi.org/10.3390/ijerph16010027
Founou, R. C., Founou, L. L., & Essack, S. Y. (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PloS one, 12(12), e0189621. https://doi.org/10.1371/journal.pone.0189621
Friedman, N. D., Temkin, E., & Carmeli, Y. (2016). The negative impact of antibiotic resistance. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 22(5), 416–422. https://doi.org/10.1016/j.cmi.2015.12.002.
Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2019). Antibiotic Discovery: Where Have We Come from, Where Do We Go?. Antibiotics (Basel, Switzerland), 8(2), 45. https://doi.org/10.3390/antibiotics8020045.
Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., Ouakrim, D. A., Oliveira, T. C., Struelens, M. J., Suetens, C., Monnet, D. L., & Burden of AMR Collaborative Group. (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet Infectious Diseases, 19(1), 56–66. https://doi.org/10.1016/S1473-3099(18)30605-4
Frieri, M., Kumar, K., & Boutin, A. (2017). Antibiotic resistance. Journal of Infection and Public Health, 10(4), 369–378. https://doi.org/10.1016/j.jiph.2016.08.007.
Shallcross, L. J., Howard, S. J., Fowler, T., & Davies, S. C. (2015). Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 370(1670), 20140082. https://doi.org/10.1098/rstb.2014.0082.
Resolución 2471 de 2022, Ministerio de salud y protección social de Colombia. Disponible en línea: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%202471%20de%202022.pdf
Hernández-Gómez, C., Blanco, V. M., Motoa, G., Correa, A., Maya, J. J., De la Cadena, E., Perengüez, M., Rojas, L., Hernández, A., Vallejo, M., & Villegas, M. V. (2013). Evolución de la resistencia antimicrobiana de bacilos Gram negativos en unidades de cuidados intensivos en Colombia. Biomedica: revista del Instituto Nacional de Salud, 34(0), 91. https://doi.org/10.7705/biomedica.v34i0.1667.
Informe de resultados de la vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS) 2018. INS. Disponible en línea: https://www.ins.gov.co/buscador-eventos/Informacin%20de%20laboratorio/Informe-vigilancia-por-laboratorio-resistencia-antimicrobiana-y-whonet-IAAS-2018.pdf
Vacca, C., Niño, C., & Reveiz, L. (2011). Restricción de la venta de AB en farmacias de Bogotá, Colombia: estudio descriptivo. Rev Panam Salud Publica, 30(6), 586–591.
Characterising the purchase of antibiotics in drugstores in Bogotá : a users ’ perspective. (2011). Rev Investig en Segur Soc y Salud, 13(1), 15–29.
Leal AL, Álvarez CA. Boletín informativo GREBO 2021. 2021;(2027):24.
Barlam, T. F., Cosgrove, S. E., Abbo, L. M., Macdougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., Hamilton, C. W., Jenkins, T. C., Lipsett, P. A., Malani, P. N., May, L. S., Moran, G. J., Neuhauser, M. M., Newland, J. G., Ohl, C. A., … Trivedi, K. K. (2016). Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis, 62(10), e51-77.
Organización Mundial de la Salud. Disponible en línea: https://www.who.int/es/news-room/fact-sheets/detail/antimicrobial-resistance.
Durand, G. A., Raoult, D., & Dubourg, G. (2019). Antibiotic discovery: history, methods and perspectives. International journal of antimicrobial agents, 53(4), 371–382. https://doi.org/10.1016/j.ijantimicag.2018.11.010.
Barlow, M., & Hall, B. G. (2002). Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. Journal of molecular evolution, 55(3), 314–321. https://doi.org/10.1007/s00239-002-2328-y
D'Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., Golding, G. B., Poinar, H. N., & Wright, G. D. (2011). Antibiotic resistance is ancient. Nature, 477(7365), 457–461. https://doi.org/10.1038/nature10388.
Lewis K. (2013). Platforms for antibiotic discovery. Nature reviews. Drug discovery, 12(5), 371–387. https://doi.org/10.1038/nrd3975
Wainwright, M. (1990). Miracle cure: the history of penicillin and the golden age of antibiotics, 38-48.
Plackett, B. (2020). Why big pharma has abandoned antibiotics. Nature, 586(7830), S50–S52. https://doi.org/10.1038/d41586-020-02884-3.
2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2022.
von Wintersdorff, C. J., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., Savelkoul, P. H., & Wolffs, P. F. (2016). Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in microbiology, 7, 173. https://doi.org/10.3389/fmicb.2016.00173.
Zhao, R., Feng, J., Liu, J., Fu, W., Li, X., & Li, B. (2019). Deciphering of microbial community and antibiotic resistance genes in activated sludge reactors under high selective pressure of different antibiotics. Water research, 151, 388–402. https://doi.org/10.1016/j.watres.2018.12.034
Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019). Global Contributors to Antibiotic Resistance. Journal of global infectious diseases, 11(1), 36–42. https://doi.org/10.4103/jgid.jgid_110_18.
Nepal, G., & Bhatta, S. (2018). Self-medication with Antibiotics in WHO Southeast Asian Region: A Systematic Review. Cureus, 10(4), e2428. https://doi.org/10.7759/cureus.2428.
Almagor, J., Temkin, E., Benenson, I., Fallach, N., & Carmeli, Y. (2018). The impact of antibi-otic use on transmission of resistant bacteria in hospitals: insights from anagent-based model. PLoS One, 13.
Manyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018). Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. Molecules (Basel, Switzerland), 23(4), 795. https://doi.org/10.3390/molecules23040795.
Rodríguez-Baño, J., Paño-Pardo, J. R., Alvarez-Rocha, L., Asensio, A., Calbo, E., Cercenado, E., Cisneros, J. M., Cobo, J., Delgado, O., Garnacho-Montero, J., Grau, S., Horcajada, J. P., Hornero, A., Murillas-Angoiti, J., Oliver, A., Padilla, B., Pasquau, J., Pujol, M., Ruiz-Garbajosa, P., San Juan, R., … Sociedad Española de Medicina Preventiva, Salud Pública e Higiene (2012). Programas de optimización de uso de AB (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH [Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document]. Enfermedades infecciosas y microbiologia clinica, 30(1), 22.e1–22.e23. https://doi.org/10.1016/j.eimc.2011.09.018.
Organización Mundial de la Salud. Programas de optimización de los AB en instituciones sanitarias de los países de ingresos bajos y medianos: manual práctico de la OMS: Organización Mundial de la Salud; 2020. Available from: https://apps.who.int/iris/handle/ 10665/335947
Orientaciones normativas de la OMS sobre las actividades integrales para la optimización de los AB [WHO policy guidance on integrated antimicrobial stewardship activities]. Ginebra: Organización Mundial de la Salud; 2021.
Monitoring and evaluation of the global action plan on antimicrobial resistance: framework and recommended indicators. Ginebra, Organización Mundial de la Salud; 2019.
Directriz para el fortalecimiento de los programas nacionales de guías informadas por la evidencia. Paho.org. Recuperado el 29 de abril de 2024, de https://iris.paho.org/bitstream/handle/10665.2/49145/9789275320167_spa.pdf?sequence=5&isAllowed=y.
No podemos esperar: Asegurar el futuro contra las infecciones farmacorresistentes. Informe para el Secretario General de las Naciones Unidas. Grupo de Coordinación Interorganismos sobre Resistencia a los AB (IACG); 2019.
Ellegård, L. M., Dietrichson, J., & Anell, A. (2018). Can pay-for-performance to primary care providers stimulate appropriate use of antibiotics?. Health economics, 27(1), e39–e54. https://doi.org/10.1002/hec.3535.
Engage-TB: integración de las actividades comunitarias de lucha contra la tuberculosis en el trabajo de las organizaciones no gubernamentales y otras organizaciones de la sociedad civil: orientaciones operacionales. Ginebra: Organización Mundial de la Salud; 2012.
Estrategia mundial de recursos humanos para la salud: personal sanitario 2030. Ginebra: Organización Mundial de la Salud; 2016.
Technical brief on water, sanitation, hygiene (WASH) and wastewater management to prevent infections and reduce the spread of antimicrobial resistance (AMR). Ginebra: Organización Mundial de la Salud; 2020.
Improving infection prevention and control at the health facility: interim practical manual supporting implementation of the WHO Guidelines on Core Components of Infection Prevention and Control Programmes. Ginebra: Organización Mundial de la Salud; 2018.
GLASS guide for national surveillance systems for monitoring antimicrobial consumption in hospitals. Ginebra: Organización Mundial de la Salud; 2020
ATC/DDD index 2021. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2021.
Global Antimicrobial Resistance Surveillance System (GLASS). Ginebra: Organización Mundial de la Salud; 2015.
Lineamientos técnicos para la implementación de programas de optimización de AB en el escenario hospitalario y ambulatorio. Asociación Colombiana de Infectología- ACIN- Capítulo Central. Ministerio de Salud y Protección Social. 2019.
Walsh, T. R., Gales, A. C., Laxminarayan, R., & Dodd, P. C. (2023). Antimicrobial Resistance: Addressing a Global Threat to Humanity. PLoS medicine, 20(7), e1004264. https://doi.org/10.1371/journal.pmed.1004264.
Aguilar, G. R., Swetschinski, L. R., Weaver, N. D., Ikuta, K. S., Mestrovic, T., Gray, A. P., Chung, E., Wool, E. E., Han, C., Hayoon, A. G., Araki, D. T., Abdollahi, A., Abu-Zaid, A., Adnan, M., Agarwal, R., Dehkordi, J. A., Aravkin, A. Y., Areda, D., Azzam, A. Y., … Naghavi, M. (2023). The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis. Lancet Regional Health. Americas, 25(100561), 100561. https://doi.org/10.1016/j.lana.2023.100561.
Lewnard, J. A., Charani, E., Gleason, A., Hsu, L. Y., Khan, W. A., Karkey, A., Chandler, C. I. R., Mashe, T., Khan, E. A., Bulabula, A. N. H., Donado-Godoy, P., & Laxminarayan, R. (2024). Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis. Lancet, 403(10442), 2439–2454. https://doi.org/10.1016/S0140-6736(24)00862-6.
Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. The Lancet Infectious Diseases, 17(9), 990–1001. https://doi.org/10.1016/s1473-3099(17)30325-0
Chrysou, K., Zarkotou, O., Kalofolia, S., Papagiannakopoulou, P., Mamali, V., Chrysos, G., Themeli-Digalaki, K., Sypsas, N., Tsakris, A., & Pournaras, S. (2022). Impact of a 4-year antimicrobial stewardship program implemented in a Greek tertiary hospital. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 41(1), 127–132. https://doi.org/10.1007/s10096-021-04290-7.
Giamarellou, H., Galani, L., Karavasilis, T., Ioannidis, K., & Karaiskos, I. (2023). Antimicrobial stewardship in the hospital setting: A narrative review. Antibiotics (Basel, Switzerland), 12(10), 1557. https://doi.org/10.3390/antibiotics12101557
Rhee, C., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., DelloStritto, L., Klompas, M., & CDC Prevention Epicenters Program. (2024). Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals. JAMA Network Open, 7(6), e2418923. https://doi.org/10.1001/jamanetworkopen.2024.18923.
Rhee, C., Kadri, S. S., Dekker, J. P., Danner, R. L., Chen, H. C., Fram, D., Zhang, F., Wang, R., Klompas, M., & CDC Prevention Epicenters Program (2020). Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA network open, 3(4), e202899. https://doi.org/10.1001/jamanetworkopen.2020.2899.
Zay Ya, K., Win, P. T. N., Bielicki, J., Lambiris, M., & Fink, G. (2023). Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. JAMA network open, 6(2), e2253806. https://doi.org/10.1001/jamanetworkopen.2022.53806.
Jhaveri, T. A., Weiss, Z. F., Winkler, M. L., Pyden, A. D., Basu, S. S., & Pecora, N. D. (2024). A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know. Antimicrobial Stewardship & Healthcare Epidemiology: ASHE, 4(1), e8. https://doi.org/10.1017/ash.2024.10
Van Heuverswyn, J., Valik, J. K., Desirée van der Werff, S., Hedberg, P., Giske, C., & Nauclér, P. (2023). Association Between Time to Appropriate Antimicrobial Treatment and 30-day Mortality in Patients With Bloodstream Infections: A Retrospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), 469–478. https://doi.org/10.1093/cid/ciac727
Peri, A. M., Chatfield, M. D., Ling, W., Furuya-Kanamori, L., Harris, P. N. A., & Paterson, D. L. (2024). Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: What is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciae234
Fabre, V., Cosgrove, S. E., Secaira, C., Tapia Torrez, J. C., Lessa, F. C., Patel, T. S., & Quiros, R. (2022). Antimicrobial stewardship in Latin America: Past, present, and future. Antimicrobial Stewardship & Healthcare Epidemiology: ASHE, 2(1), e68. https://doi.org/10.1017/ash.2022.47
Romo-Castillo, H. F., & Pazin-Filho, A. (2022). Towards implementing an antibiotic stewardship programme (ASP) in Ecuador: evaluating antibiotic consumption and the impact of an ASP in a tertiary hospital according to World Health Organization (WHO) recommendations. Journal of global antimicrobial resistance, 29, 462–467. https://doi.org/10.1016/j.jgar.2021.11.001.
Doltrario, A. B., Gaspar, G. G., Ungari, A. Q., Martinez, R., Pazin Filho, A., Maciel, B. C., Bellissimo-Rodrigues, F., & Santana, R. C. (2022). Assessment of preauthorization and 24-hour expert consultation as a restrictive antimicrobial stewardship bundle in a Brazilian tertiary-care hospital: an interrupted time series analysis. Infection prevention in practice, 4(1), 100201. https://doi.org/10.1016/j.infpip.2022.100201.
Pallares, C. J., Porras, J., De La Cadena, E., García-Betancur, J. C., Restrepo-Arbeláez, N., Viveros, S. M. C., Cornistein, W., Castañeda-Méndez, P., Cuellar, L., Boldim-Ferreira, D., Chaverri-Murillo, J., Labarca, J. A., & Villegas, M. V. (2023). Antimicrobial stewardship programs in seven Latin American countries: facing the challenges. BMC Infectious Diseases, 23(1), 463. https://doi.org/10.1186/s12879-023-08398-3
Restrepo-Arbeláez, N., Garcia-Betancur, J. C., Pallares, C. J., & Villegas, M. V. (2023). Antimicrobial stewardship programs in Latin America and the Caribbean: A story of perseverance, challenges, and goals. Antibiotics (Basel, Switzerland), 12(8). https://doi.org/10.3390/antibiotics12081342
Jiménez Pearson, M. A., Galas, M., Corso, A., Hormazábal, J. C., Duarte Valderrama, C., Salgado Marcano, N., Ramón-Pardo, P., & Melano, R. G. (2019). Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes [Latin American consensus to define, categorize, and report multidrug-resistant, extensively drug-resistant, or pandrug-resistant pathogensConsenso latino-americano para definição, categorização e notificação de patógenos multirresistentes, com resistência ampliada ou panresistentes]. Revista panamericana de salud publica = Pan American journal of public health, 43, e65. https://doi.org/10.26633/RPSP.2019.65.
McGowan, J. E., Jr, & Gerding, D. N. (1996). Does antibiotic restriction prevent resistance? New horizons (Baltimore, Md.), 4(3), 370–376
Shlaes, D. M., Gerding, D. N., John, J. F., Jr, Craig, W. A., Bornstein, D. L., Duncan, R. A., Eckman, M. R., Farrer, W. E., Greene, W. H., Lorian, V., Levy, S., McGowan, J. E., Jr, Paul, S. M., Ruskin, J., Tenover, F. C., & Watanakunakorn, C. (1997). Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 25(3), 584–599. https://doi.org/10.1086/513766.
The Copenhagen Recomendations. Report from the invitational EU conference on The Microbial Threat. Copenhagen, Denmark. Sept. 9-10. 1998
World Health Assembly. (1998). Emerging and other communicable diseases: antimicrobial resistance. World Health Organization.
Dellit, T. H., Owens, R. C., McGowan, J. E., Jr, Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., Brennan, P. J., Billeter, M., Hooton, T. M., Infectious Diseases Society of America, & Society for Healthcare Epidemiology of America (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 44(2), 159–177. https://doi.org/10.1086/510393.
Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017). What is antimicrobial stewardship? Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 23(11), 793-798. https://doi.org/10.1016/j.cmi.2017.08.026.
Centers for Disease Control and Prevention. Antibiotic Rx in hospitals: proceed with caution. Vital Signs, March 2014. www.cdc.gov/vitalsigns/pdf/2014-03-vitalsigns.pdf
CDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.
Colombia. Institute for Health Metrics and Evaluation. Recuperado el 14 de junio de 2024, de https://www.healthdata.org/research-analysis/health-by-location/profiles/Colombia.
Reyes, R. E., López, M. J., Pérez, J. E., & Martínez, G. (2023). Description of changes in clinical outcomes following the implementation of an antibiotic stewardship program in a level IV hospital. Descripción del cambio en desenlaces clínicos posteriores a la implementación de un programa de gestión de AB en un hospital de cuarto nivel de atención en salud. Biomédica : revista del Instituto Nacional de Salud, 43(2), 244–251. https://doi.org/10.7705/biomedica.6748
Ortiz, G., Dueñas, C., Rodríguez, F., Barrera, L., de La Rosa, G., Dennis, R., Jaimes, F. (2014). Epidemiología de la sepsis en unidades de cuidado intensivo en Colombia. Biomédica, 34(1), 40–7. https://doi.org/10.7705/biomedica.v34i1.1439.
Liu, P., Ohl, C., Johnson, J., Williamson, J., Beardsley, J., & Luther, V. (2016). Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program. BMC infectious diseases, 16(1), 751. https://doi.org/10.1186/s12879-016-2080-3.
Daniel J Livorsi, Rajeshwari Nair, Brian C Lund, Bruce Alexander, Brice F Beck, Michihiko Goto, Michael Ohl, Mary S Vaughan-Sarrazin, Matthew B Goetz, Eli N Perencevich, Antibiotic Stewardship Implementation and Antibiotic Use at Hospitals with and Without On-site Infectious Disease Specialists, Clinical Infectious Diseases, Volume 72, Issue 10, 15 May 2021, Pages 1810–1817, https://doi.org/10.1093/cid/ciaa388.
De Bus, L., Depuydt, P., Steen, J., Dhaese, S., De Smet, K., Tabah, A., Akova, M., Cotta, M. O., De Pascale, G., Dimopoulos, G., Fujitani, S., Garnacho-Montero, J., Leone, M., Lipman, J., Ostermann, M., Paiva, J. A., Schouten, J., Sjövall, F., Timsit, J. F., Roberts, J. A., the DIANA study group (2020). Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive care medicine, 46(7), 1404–1417. https://doi.org/10.1007/s00134-020-06111-5.
Zay Ya, K., Win, P. T. N., Bielicki, J., Lambiris, M., & Fink, G. (2023). Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. JAMA network open, 6(2), e2253806. https://doi.org/10.1001/jamanetworkopen.2022.53806.
Royer, S., DeMerle, K. M., Dickson, R. P., & Prescott, H. C. (2018). Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis. Journal of hospital medicine, 13(5), 336–342. https://doi.org/10.12788/jhm.2905
Mo, Y., Oonsivilai, M., Lim, C., Niehus, R., & Cooper, B. S. (2023). Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis. PLoS medicine, 20(6), e1004013. https://doi.org/10.1371/journal.pmed.1004013.
Leone, M., Bechis, C., Baumstarck, K., Lefrant, J. Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J. M., Papazian, L., Bruder, N., Allaouchiche, B., Bézulier, K., Antonini, F., Textoris, J., Martin, C., & AZUREA Network Investigators (2014). De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive care medicine, 40(10), 1399–1408. https://doi.org/10.1007/s00134-014-3411-8.
Lakbar, I., De Waele, J.J., Tabah, A. et al. Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence. Adv Ther 37, 3083–3096 (2020). https://doi.org/10.1007/s12325-020-01390-2.
Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. 2016. Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs. Antimicrob Agents Chemother 60: https://doi.org/10.1128/aac.00825-16.
Madden, G. R., Weinstein, R. A., & Sifri, C. D. (2018). Diagnostic Stewardship for Healthcare-Associated Infections: Opportunities and Challenges to Safely Reduce Test Use. Infection control and hospital epidemiology, 39(2), 214–218. https://doi.org/10.1017/ice.2017.278.
Zakhour, J., Haddad, S. F., Kerbage, A., Wertheim, H., Tattevin, P., Voss, A., Ünal, S., Ouedraogo, A. S., Kanj, S. S., & International Society of Antimicrobial Chemotherapy (ISAC) and the Alliance for the Prudent Use of Antibiotics (APUA) (2023). Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. International journal of antimicrobial agents, 62(1), 106816. https://doi.org/10.1016/j.ijantimicag.2023.106816.
Vaughn, V. M., Gupta, A., Petty, L. A., Malani, A. N., Osterholzer, D., Patel, P. K., Younas, M., Bernstein, S. J., Burdick, S., Ratz, D., Szymczak, J. E., McLaughlin, E., Czilok, T., Basu, T., Horowitz, J. K., Flanders, S. A., & Gandhi, T. N. (2023). A Statewide Quality Initiative to Reduce Unnecessary Antibiotic Treatment of Asymptomatic Bacteriuria. JAMA internal medicine, 183(9), 933–941. https://doi.org/10.1001/jamainternmed.2023.2749.
Fabre, V., Davis, A., Diekema, D. J., Granwehr, B., Hayden, M. K., Lowe, C. F., Pfeiffer, C. D., Sick-Samuels, A. C., Sullivan, K. V., Van Schooneveld, T. C., & Morgan, D. J. (2023). Principles of diagnostic stewardship: A practical guide from the Society for Healthcare Epidemiology of America Diagnostic Stewardship Task Force. Infection control and hospital epidemiology, 44(2), 178–185. https://doi.org/10.1017/ice.2023.5
Peri, A. M., Chatfield, M. D., Ling, W., Furuya-Kanamori, L., Harris, P. N. A., & Paterson, D. L. (2024). Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: What is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciae234
Instituto nacional de salud (2024). Informe de evento. Infecciones asociadas a dispositivos. Recuperado junio de 2024, de https://www.ins.gov.co/buscador- eventos/Informesdeevento/IAD%20ABRIL%202024.pdf
dc.source.instname.none.fl_str_mv instname:Universidad del Rosario
dc.source.reponame.none.fl_str_mv reponame:Repositorio Institucional EdocUR
bitstream.url.fl_str_mv https://repository.urosario.edu.co/bitstreams/6bc1b3c9-0ae5-4022-b8d8-0fcd87863a4f/download
https://repository.urosario.edu.co/bitstreams/a8113713-cb51-435d-bc14-a51c611429ac/download
https://repository.urosario.edu.co/bitstreams/b52c1439-08ba-4302-b378-98ccff002fd5/download
https://repository.urosario.edu.co/bitstreams/780fb8cf-f7d9-4839-8f16-c7d67e8381be/download
https://repository.urosario.edu.co/bitstreams/4e65bc68-977a-44a7-9fc3-a75d972cf777/download
bitstream.checksum.fl_str_mv bbe9abc9532dd30e3619618ce4490bb2
b2825df9f458e9d5d96ee8b7cd74fde6
5643bfd9bcf29d560eeec56d584edaa9
29c40fe1258fcf7c3c1fdbd3ecad2b37
2e84b15a0f0b92c5a203ca521acef75e
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
MD5
MD5
repository.name.fl_str_mv Repositorio institucional EdocUR
repository.mail.fl_str_mv edocur@urosario.edu.co
_version_ 1814167634726354944
spelling Pérez Franco, Jairo Enrique338842f0-467a-4b6a-bbf2-d824f6280c8c-1Cruz Reyes, Danna Lesley1032415315600López, María Joséd937a809-ce78-4a08-9259-a98b76f34267-1Polanía Guzmán, Eduardo JoséEspecialista en InfectologíaMaestríaFull time1844770e-c0eb-4bf6-b69f-5c3affad25a5-12024-08-06T18:11:27Z2024-08-06T18:11:27Z2024-08-01info:eu-repo/date/embargoEnd/2025-08-08Los PROA (Programa de Optimización de antimicrobianos) tienen como finalidad evaluar y fortalecer el uso apropiado de antimicrobianos (AB), por medio del conocimiento y educación para seleccionar el régimen óptimo que brinde mejores desenlaces clínicos, menos eventos adversos, llevar a metas de control de infecciones intrahospitalarias, menores tasas de resistencia a AB y reducir costos en salud. Es importante generar estudios epidemiológicos que aporten datos de las intervenciones en los PROA y así evaluar su desempeño. Objetivos: Describir las principales características clínicas y terapéuticas de un programa de optimización de tratamiento antimicrobiano en pacientes atendidos por diferentes servicios médicos y con patologías infecciosas en una institución de salud de IV nivel de Bogotá – Colombia. Métodos: Estudio observacional, descriptivo y de corte transversal. Datos retrospectivos obtenidos de los registros originales del PROA. Recopilación de datos se para los años 2015 al 2018. La población estuvo compuesta por pacientes mayores de 18 años hospitalizados por patologías infecciosas que requirieron tratamiento AB. Resultados: Se obtuvieron datos de las historias clínicas de 10.886 pacientes de los que se analizaron 9379. La edad promedio 65.5 años (desviación estándar (DE) 18,1 años) , y 4964 (53,1%) mujeres. El diagnóstico más frecuente fue infección de vías urinarias (IVU) 21%, seguido de neumonía/empiema 15.4%. El 81,1% de las prescripciones son consideradas bien formuladas. Piperacilina tazobactam el AB más frecuentemente formulado 41%. Se describe 15.6% de sospecha de infecciones asociadas a la atención en salud (IAAS). El tiempo en promedio hasta el desescalamiento AB no superó 3.1 días (DE=2,2 días). El porcentaje de intervenciones por infectología (modificación o suspensión de terapia) estuvo entre 53,5% y 59.7% durante los años del estudio. Hubo una reducción en el promedio de los días programados de tratamiento por los años del estudio, 2016: 11 días en contraste con 2018: 6 días. Conclusiones: Las infecciones más frecuentes que implican atención hospitalaria y prescripción de AB son: infección de vías urinarias (IVU), neumonía/empiemas, Apendicitis/peritonitis/absceso intraabdominal, Choque séptico/sepsis de foco a esclarecer. Los AB más frecuentemente prescritos para estas infecciones son: piperacilina tazobactam, vancomicina, meropenem, ertapenem y ceftriaxona. Un porcentaje significativo de los pacientes con AB tuvieron formulaciones acertadas, y aún en estos casos la prescripción se puede optimizar. La optimización se puede hacer con base en guías de manejo o de realización y análisis de reportes microbiológicos por un programa PROA.The purpose of the Antimicrobial Stewardship is to evaluate and strengthen the appropriate use of antimicrobials, through knowledge and education to select the optimal regimen that provides better clinical outcomes, fewer adverse events, and leads to hospital infection control, lower rates of antimicrobial resistance and reduce health costs. It is important to generate epidemiological studies that provide data on Antimicrobial Stewardship interventions and thus evaluate their performance. Objectives: Describe the main characteristics of an Antimicrobial Stewardship in patients treated by different medical services and with infectious pathologies in high level of care hospital institution in Bogotá – Colombia. Methods: Observational, descriptive and retrospective cross-sectional study. Data obtained from medical records. Data collection will be carried out for the years 2015 to 2018. The population was composed of patients over 18 years of age hospitalized for infectious pathologies that required antimicrobial treatment. Results: Data were obtained from the medical records of 10,886 patients, of which 9,379 were analyzed. The average age was 65.5 years (standard deviation 18,1 years), 4,964 (53.1%) were women. The most frequent diagnosis was urinary tract infection (UTI) 21%, followed by pneumonia/empyema 15.4%. 81.1% of the recipes are considered well formulated. Piperacillin tazobactam the most frequently formulated antibiotic 41%. 15.6% of suspected healthcare-associated infections (HAIs) are described. The average time to antimicrobial de-escalation (ADE) did not exceed 3.1 days (standard deviation 2,2 days). The percentage of interventions due to infectious disease specialists (modification or suspension of therapy) was between 53.5% and 59.7% during the years of the study. There was a reduction in the average number of days scheduled for treatment by the years of the study, 2016: 11 days in contrast to 2018: 6 days. Conclusions: The most frequent infections that involve hospital care and antimicrobial prescription are urinary tract infection (UTI), pneumonia/empyema, Appendicitis/peritonitis/intra-abdominal abscess, Septic shock/sepsis of focus to be clarified. The most frequently prescribed antimicrobial for these infections are: piperacillin tazobactam, vancomycin, meropenem, ertapenem and ceftriaxone. A significant percentage of patients with antimicrobial treatment had correct formulations, and even in these cases the prescription can be optimized. Optimization can be done based on management guides or the preparation and analysis of microbiological reports by an Antimicrobial Stewardship.86 PPapplication/pdfhttps://repository.urosario.edu.co/handle/10336/43229spaUniversidad del RosarioEscuela de Medicina y Ciencias de la SaludEspecialización en InfectologíaAttribution-NonCommercial-ShareAlike 4.0 InternationalAbierto (Texto Completo)EL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.http://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2Spellberg, B. (121). Mandell, Douglas, Bennett. Enfermedades infecciosas. Principios y práctica (Novena ed., Vol. I, pp. 211-221). Elsevier EspañaUddin, T. M., Chakraborty, A. J., Khusro, A., Zidan, B. R. M., Mitra, S., Emran, T. B., Dhama, K., Ripon, M. K. H., Gajdács, M., Sahibzada, M. U. K., Hossain, M. J., & Koirala, N. (2021). Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. Journal of Infection and Public Health, 14(12), 1750–1766. https://doi.org/10.1016/j.jiph.2021.10.020Huijbers, P. M. C., Blaak, H., de Jong, M. C. M., Graat, E. A. M., Vandenbroucke-Grauls, C. M. J. E., & de Roda Husman, A. M. (2015). Role of the environment in the transmission of antimicrobial resistance to humans: A review. Environmental Science & Technology, 49(20), 11993–12004. https://doi.org/10.1021/acs.est.5b02566Machowska, A., & Stålsby Lundborg, C. (2018). Drivers of irrational use of antibiotics in Europe. International Journal of Environmental Research and Public Health, 16(1), 27. https://doi.org/10.3390/ijerph16010027Founou, R. C., Founou, L. L., & Essack, S. Y. (2017). Clinical and economic impact of antibiotic resistance in developing countries: A systematic review and meta-analysis. PloS one, 12(12), e0189621. https://doi.org/10.1371/journal.pone.0189621Friedman, N. D., Temkin, E., & Carmeli, Y. (2016). The negative impact of antibiotic resistance. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 22(5), 416–422. https://doi.org/10.1016/j.cmi.2015.12.002.Ribeiro da Cunha, B., Fonseca, L. P., & Calado, C. R. C. (2019). Antibiotic Discovery: Where Have We Come from, Where Do We Go?. Antibiotics (Basel, Switzerland), 8(2), 45. https://doi.org/10.3390/antibiotics8020045.Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., Ouakrim, D. A., Oliveira, T. C., Struelens, M. J., Suetens, C., Monnet, D. L., & Burden of AMR Collaborative Group. (2019). Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. The Lancet Infectious Diseases, 19(1), 56–66. https://doi.org/10.1016/S1473-3099(18)30605-4Frieri, M., Kumar, K., & Boutin, A. (2017). Antibiotic resistance. Journal of Infection and Public Health, 10(4), 369–378. https://doi.org/10.1016/j.jiph.2016.08.007.Shallcross, L. J., Howard, S. J., Fowler, T., & Davies, S. C. (2015). Tackling the threat of antimicrobial resistance: from policy to sustainable action. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 370(1670), 20140082. https://doi.org/10.1098/rstb.2014.0082.Resolución 2471 de 2022, Ministerio de salud y protección social de Colombia. Disponible en línea: https://www.minsalud.gov.co/Normatividad_Nuevo/Resoluci%C3%B3n%20No.%202471%20de%202022.pdfHernández-Gómez, C., Blanco, V. M., Motoa, G., Correa, A., Maya, J. J., De la Cadena, E., Perengüez, M., Rojas, L., Hernández, A., Vallejo, M., & Villegas, M. V. (2013). Evolución de la resistencia antimicrobiana de bacilos Gram negativos en unidades de cuidados intensivos en Colombia. Biomedica: revista del Instituto Nacional de Salud, 34(0), 91. https://doi.org/10.7705/biomedica.v34i0.1667.Informe de resultados de la vigilancia por laboratorio de resistencia antimicrobiana en infecciones asociadas a la atención en salud (IAAS) 2018. INS. Disponible en línea: https://www.ins.gov.co/buscador-eventos/Informacin%20de%20laboratorio/Informe-vigilancia-por-laboratorio-resistencia-antimicrobiana-y-whonet-IAAS-2018.pdfVacca, C., Niño, C., & Reveiz, L. (2011). Restricción de la venta de AB en farmacias de Bogotá, Colombia: estudio descriptivo. Rev Panam Salud Publica, 30(6), 586–591.Characterising the purchase of antibiotics in drugstores in Bogotá : a users ’ perspective. (2011). Rev Investig en Segur Soc y Salud, 13(1), 15–29.Leal AL, Álvarez CA. Boletín informativo GREBO 2021. 2021;(2027):24.Barlam, T. F., Cosgrove, S. E., Abbo, L. M., Macdougall, C., Schuetz, A. N., Septimus, E. J., Srinivasan, A., Dellit, T. H., Falck-Ytter, Y. T., Fishman, N. O., Hamilton, C. W., Jenkins, T. C., Lipsett, P. A., Malani, P. N., May, L. S., Moran, G. J., Neuhauser, M. M., Newland, J. G., Ohl, C. A., … Trivedi, K. K. (2016). Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis, 62(10), e51-77.Organización Mundial de la Salud. Disponible en línea: https://www.who.int/es/news-room/fact-sheets/detail/antimicrobial-resistance.Durand, G. A., Raoult, D., & Dubourg, G. (2019). Antibiotic discovery: history, methods and perspectives. International journal of antimicrobial agents, 53(4), 371–382. https://doi.org/10.1016/j.ijantimicag.2018.11.010.Barlow, M., & Hall, B. G. (2002). Phylogenetic analysis shows that the OXA beta-lactamase genes have been on plasmids for millions of years. Journal of molecular evolution, 55(3), 314–321. https://doi.org/10.1007/s00239-002-2328-yD'Costa, V. M., King, C. E., Kalan, L., Morar, M., Sung, W. W., Schwarz, C., Froese, D., Zazula, G., Calmels, F., Debruyne, R., Golding, G. B., Poinar, H. N., & Wright, G. D. (2011). Antibiotic resistance is ancient. Nature, 477(7365), 457–461. https://doi.org/10.1038/nature10388.Lewis K. (2013). Platforms for antibiotic discovery. Nature reviews. Drug discovery, 12(5), 371–387. https://doi.org/10.1038/nrd3975Wainwright, M. (1990). Miracle cure: the history of penicillin and the golden age of antibiotics, 38-48.Plackett, B. (2020). Why big pharma has abandoned antibiotics. Nature, 586(7830), S50–S52. https://doi.org/10.1038/d41586-020-02884-3.2021 Antibacterial agents in clinical and preclinical development: an overview and analysis. Geneva: World Health Organization; 2022.von Wintersdorff, C. J., Penders, J., van Niekerk, J. M., Mills, N. D., Majumder, S., van Alphen, L. B., Savelkoul, P. H., & Wolffs, P. F. (2016). Dissemination of Antimicrobial Resistance in Microbial Ecosystems through Horizontal Gene Transfer. Frontiers in microbiology, 7, 173. https://doi.org/10.3389/fmicb.2016.00173.Zhao, R., Feng, J., Liu, J., Fu, W., Li, X., & Li, B. (2019). Deciphering of microbial community and antibiotic resistance genes in activated sludge reactors under high selective pressure of different antibiotics. Water research, 151, 388–402. https://doi.org/10.1016/j.watres.2018.12.034Chokshi, A., Sifri, Z., Cennimo, D., & Horng, H. (2019). Global Contributors to Antibiotic Resistance. Journal of global infectious diseases, 11(1), 36–42. https://doi.org/10.4103/jgid.jgid_110_18.Nepal, G., & Bhatta, S. (2018). Self-medication with Antibiotics in WHO Southeast Asian Region: A Systematic Review. Cureus, 10(4), e2428. https://doi.org/10.7759/cureus.2428.Almagor, J., Temkin, E., Benenson, I., Fallach, N., & Carmeli, Y. (2018). The impact of antibi-otic use on transmission of resistant bacteria in hospitals: insights from anagent-based model. PLoS One, 13.Manyi-Loh, C., Mamphweli, S., Meyer, E., & Okoh, A. (2018). Antibiotic Use in Agriculture and Its Consequential Resistance in Environmental Sources: Potential Public Health Implications. Molecules (Basel, Switzerland), 23(4), 795. https://doi.org/10.3390/molecules23040795.Rodríguez-Baño, J., Paño-Pardo, J. R., Alvarez-Rocha, L., Asensio, A., Calbo, E., Cercenado, E., Cisneros, J. M., Cobo, J., Delgado, O., Garnacho-Montero, J., Grau, S., Horcajada, J. P., Hornero, A., Murillas-Angoiti, J., Oliver, A., Padilla, B., Pasquau, J., Pujol, M., Ruiz-Garbajosa, P., San Juan, R., … Sociedad Española de Medicina Preventiva, Salud Pública e Higiene (2012). Programas de optimización de uso de AB (PROA) en hospitales españoles: documento de consenso GEIH-SEIMC, SEFH y SEMPSPH [Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC, SEFH and SEMPSPH consensus document]. Enfermedades infecciosas y microbiologia clinica, 30(1), 22.e1–22.e23. https://doi.org/10.1016/j.eimc.2011.09.018.Organización Mundial de la Salud. Programas de optimización de los AB en instituciones sanitarias de los países de ingresos bajos y medianos: manual práctico de la OMS: Organización Mundial de la Salud; 2020. Available from: https://apps.who.int/iris/handle/ 10665/335947Orientaciones normativas de la OMS sobre las actividades integrales para la optimización de los AB [WHO policy guidance on integrated antimicrobial stewardship activities]. Ginebra: Organización Mundial de la Salud; 2021.Monitoring and evaluation of the global action plan on antimicrobial resistance: framework and recommended indicators. Ginebra, Organización Mundial de la Salud; 2019.Directriz para el fortalecimiento de los programas nacionales de guías informadas por la evidencia. Paho.org. Recuperado el 29 de abril de 2024, de https://iris.paho.org/bitstream/handle/10665.2/49145/9789275320167_spa.pdf?sequence=5&isAllowed=y.No podemos esperar: Asegurar el futuro contra las infecciones farmacorresistentes. Informe para el Secretario General de las Naciones Unidas. Grupo de Coordinación Interorganismos sobre Resistencia a los AB (IACG); 2019.Ellegård, L. M., Dietrichson, J., & Anell, A. (2018). Can pay-for-performance to primary care providers stimulate appropriate use of antibiotics?. Health economics, 27(1), e39–e54. https://doi.org/10.1002/hec.3535.Engage-TB: integración de las actividades comunitarias de lucha contra la tuberculosis en el trabajo de las organizaciones no gubernamentales y otras organizaciones de la sociedad civil: orientaciones operacionales. Ginebra: Organización Mundial de la Salud; 2012.Estrategia mundial de recursos humanos para la salud: personal sanitario 2030. Ginebra: Organización Mundial de la Salud; 2016.Technical brief on water, sanitation, hygiene (WASH) and wastewater management to prevent infections and reduce the spread of antimicrobial resistance (AMR). Ginebra: Organización Mundial de la Salud; 2020.Improving infection prevention and control at the health facility: interim practical manual supporting implementation of the WHO Guidelines on Core Components of Infection Prevention and Control Programmes. Ginebra: Organización Mundial de la Salud; 2018.GLASS guide for national surveillance systems for monitoring antimicrobial consumption in hospitals. Ginebra: Organización Mundial de la Salud; 2020ATC/DDD index 2021. Oslo: WHO Collaborating Centre for Drug Statistics Methodology; 2021.Global Antimicrobial Resistance Surveillance System (GLASS). Ginebra: Organización Mundial de la Salud; 2015.Lineamientos técnicos para la implementación de programas de optimización de AB en el escenario hospitalario y ambulatorio. Asociación Colombiana de Infectología- ACIN- Capítulo Central. Ministerio de Salud y Protección Social. 2019.Walsh, T. R., Gales, A. C., Laxminarayan, R., & Dodd, P. C. (2023). Antimicrobial Resistance: Addressing a Global Threat to Humanity. PLoS medicine, 20(7), e1004264. https://doi.org/10.1371/journal.pmed.1004264.Aguilar, G. R., Swetschinski, L. R., Weaver, N. D., Ikuta, K. S., Mestrovic, T., Gray, A. P., Chung, E., Wool, E. E., Han, C., Hayoon, A. G., Araki, D. T., Abdollahi, A., Abu-Zaid, A., Adnan, M., Agarwal, R., Dehkordi, J. A., Aravkin, A. Y., Areda, D., Azzam, A. Y., … Naghavi, M. (2023). The burden of antimicrobial resistance in the Americas in 2019: a cross-country systematic analysis. Lancet Regional Health. Americas, 25(100561), 100561. https://doi.org/10.1016/j.lana.2023.100561.Lewnard, J. A., Charani, E., Gleason, A., Hsu, L. Y., Khan, W. A., Karkey, A., Chandler, C. I. R., Mashe, T., Khan, E. A., Bulabula, A. N. H., Donado-Godoy, P., & Laxminarayan, R. (2024). Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis. Lancet, 403(10442), 2439–2454. https://doi.org/10.1016/S0140-6736(24)00862-6.Baur, D., Gladstone, B. P., Burkert, F., Carrara, E., Foschi, F., Döbele, S., & Tacconelli, E. (2017). Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and Clostridium difficile infection: a systematic review and meta-analysis. The Lancet Infectious Diseases, 17(9), 990–1001. https://doi.org/10.1016/s1473-3099(17)30325-0Chrysou, K., Zarkotou, O., Kalofolia, S., Papagiannakopoulou, P., Mamali, V., Chrysos, G., Themeli-Digalaki, K., Sypsas, N., Tsakris, A., & Pournaras, S. (2022). Impact of a 4-year antimicrobial stewardship program implemented in a Greek tertiary hospital. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology, 41(1), 127–132. https://doi.org/10.1007/s10096-021-04290-7.Giamarellou, H., Galani, L., Karavasilis, T., Ioannidis, K., & Karaiskos, I. (2023). Antimicrobial stewardship in the hospital setting: A narrative review. Antibiotics (Basel, Switzerland), 12(10), 1557. https://doi.org/10.3390/antibiotics12101557Rhee, C., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., DelloStritto, L., Klompas, M., & CDC Prevention Epicenters Program. (2024). Trends in empiric broad-spectrum antibiotic use for suspected community-onset sepsis in US hospitals. JAMA Network Open, 7(6), e2418923. https://doi.org/10.1001/jamanetworkopen.2024.18923.Rhee, C., Kadri, S. S., Dekker, J. P., Danner, R. L., Chen, H. C., Fram, D., Zhang, F., Wang, R., Klompas, M., & CDC Prevention Epicenters Program (2020). Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use. JAMA network open, 3(4), e202899. https://doi.org/10.1001/jamanetworkopen.2020.2899.Zay Ya, K., Win, P. T. N., Bielicki, J., Lambiris, M., & Fink, G. (2023). Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. JAMA network open, 6(2), e2253806. https://doi.org/10.1001/jamanetworkopen.2022.53806.Jhaveri, T. A., Weiss, Z. F., Winkler, M. L., Pyden, A. D., Basu, S. S., & Pecora, N. D. (2024). A decade of clinical microbiology: top 10 advances in 10 years: what every infection preventionist and antimicrobial steward should know. Antimicrobial Stewardship & Healthcare Epidemiology: ASHE, 4(1), e8. https://doi.org/10.1017/ash.2024.10Van Heuverswyn, J., Valik, J. K., Desirée van der Werff, S., Hedberg, P., Giske, C., & Nauclér, P. (2023). Association Between Time to Appropriate Antimicrobial Treatment and 30-day Mortality in Patients With Bloodstream Infections: A Retrospective Cohort Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3), 469–478. https://doi.org/10.1093/cid/ciac727Peri, A. M., Chatfield, M. D., Ling, W., Furuya-Kanamori, L., Harris, P. N. A., & Paterson, D. L. (2024). Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: What is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciae234Fabre, V., Cosgrove, S. E., Secaira, C., Tapia Torrez, J. C., Lessa, F. C., Patel, T. S., & Quiros, R. (2022). Antimicrobial stewardship in Latin America: Past, present, and future. Antimicrobial Stewardship & Healthcare Epidemiology: ASHE, 2(1), e68. https://doi.org/10.1017/ash.2022.47Romo-Castillo, H. F., & Pazin-Filho, A. (2022). Towards implementing an antibiotic stewardship programme (ASP) in Ecuador: evaluating antibiotic consumption and the impact of an ASP in a tertiary hospital according to World Health Organization (WHO) recommendations. Journal of global antimicrobial resistance, 29, 462–467. https://doi.org/10.1016/j.jgar.2021.11.001.Doltrario, A. B., Gaspar, G. G., Ungari, A. Q., Martinez, R., Pazin Filho, A., Maciel, B. C., Bellissimo-Rodrigues, F., & Santana, R. C. (2022). Assessment of preauthorization and 24-hour expert consultation as a restrictive antimicrobial stewardship bundle in a Brazilian tertiary-care hospital: an interrupted time series analysis. Infection prevention in practice, 4(1), 100201. https://doi.org/10.1016/j.infpip.2022.100201.Pallares, C. J., Porras, J., De La Cadena, E., García-Betancur, J. C., Restrepo-Arbeláez, N., Viveros, S. M. C., Cornistein, W., Castañeda-Méndez, P., Cuellar, L., Boldim-Ferreira, D., Chaverri-Murillo, J., Labarca, J. A., & Villegas, M. V. (2023). Antimicrobial stewardship programs in seven Latin American countries: facing the challenges. BMC Infectious Diseases, 23(1), 463. https://doi.org/10.1186/s12879-023-08398-3Restrepo-Arbeláez, N., Garcia-Betancur, J. C., Pallares, C. J., & Villegas, M. V. (2023). Antimicrobial stewardship programs in Latin America and the Caribbean: A story of perseverance, challenges, and goals. Antibiotics (Basel, Switzerland), 12(8). https://doi.org/10.3390/antibiotics12081342Jiménez Pearson, M. A., Galas, M., Corso, A., Hormazábal, J. C., Duarte Valderrama, C., Salgado Marcano, N., Ramón-Pardo, P., & Melano, R. G. (2019). Consenso latinoamericano para definir, categorizar y notificar patógenos multirresistentes, con resistencia extendida o panresistentes [Latin American consensus to define, categorize, and report multidrug-resistant, extensively drug-resistant, or pandrug-resistant pathogensConsenso latino-americano para definição, categorização e notificação de patógenos multirresistentes, com resistência ampliada ou panresistentes]. Revista panamericana de salud publica = Pan American journal of public health, 43, e65. https://doi.org/10.26633/RPSP.2019.65.McGowan, J. E., Jr, & Gerding, D. N. (1996). Does antibiotic restriction prevent resistance? New horizons (Baltimore, Md.), 4(3), 370–376Shlaes, D. M., Gerding, D. N., John, J. F., Jr, Craig, W. A., Bornstein, D. L., Duncan, R. A., Eckman, M. R., Farrer, W. E., Greene, W. H., Lorian, V., Levy, S., McGowan, J. E., Jr, Paul, S. M., Ruskin, J., Tenover, F. C., & Watanakunakorn, C. (1997). Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 25(3), 584–599. https://doi.org/10.1086/513766.The Copenhagen Recomendations. Report from the invitational EU conference on The Microbial Threat. Copenhagen, Denmark. Sept. 9-10. 1998World Health Assembly. (1998). Emerging and other communicable diseases: antimicrobial resistance. World Health Organization.Dellit, T. H., Owens, R. C., McGowan, J. E., Jr, Gerding, D. N., Weinstein, R. A., Burke, J. P., Huskins, W. C., Paterson, D. L., Fishman, N. O., Carpenter, C. F., Brennan, P. J., Billeter, M., Hooton, T. M., Infectious Diseases Society of America, & Society for Healthcare Epidemiology of America (2007). Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 44(2), 159–177. https://doi.org/10.1086/510393.Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017). What is antimicrobial stewardship? Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 23(11), 793-798. https://doi.org/10.1016/j.cmi.2017.08.026.Centers for Disease Control and Prevention. Antibiotic Rx in hospitals: proceed with caution. Vital Signs, March 2014. www.cdc.gov/vitalsigns/pdf/2014-03-vitalsigns.pdfCDC. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.Colombia. Institute for Health Metrics and Evaluation. Recuperado el 14 de junio de 2024, de https://www.healthdata.org/research-analysis/health-by-location/profiles/Colombia.Reyes, R. E., López, M. J., Pérez, J. E., & Martínez, G. (2023). Description of changes in clinical outcomes following the implementation of an antibiotic stewardship program in a level IV hospital. Descripción del cambio en desenlaces clínicos posteriores a la implementación de un programa de gestión de AB en un hospital de cuarto nivel de atención en salud. Biomédica : revista del Instituto Nacional de Salud, 43(2), 244–251. https://doi.org/10.7705/biomedica.6748Ortiz, G., Dueñas, C., Rodríguez, F., Barrera, L., de La Rosa, G., Dennis, R., Jaimes, F. (2014). Epidemiología de la sepsis en unidades de cuidado intensivo en Colombia. Biomédica, 34(1), 40–7. https://doi.org/10.7705/biomedica.v34i1.1439.Liu, P., Ohl, C., Johnson, J., Williamson, J., Beardsley, J., & Luther, V. (2016). Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program. BMC infectious diseases, 16(1), 751. https://doi.org/10.1186/s12879-016-2080-3.Daniel J Livorsi, Rajeshwari Nair, Brian C Lund, Bruce Alexander, Brice F Beck, Michihiko Goto, Michael Ohl, Mary S Vaughan-Sarrazin, Matthew B Goetz, Eli N Perencevich, Antibiotic Stewardship Implementation and Antibiotic Use at Hospitals with and Without On-site Infectious Disease Specialists, Clinical Infectious Diseases, Volume 72, Issue 10, 15 May 2021, Pages 1810–1817, https://doi.org/10.1093/cid/ciaa388.De Bus, L., Depuydt, P., Steen, J., Dhaese, S., De Smet, K., Tabah, A., Akova, M., Cotta, M. O., De Pascale, G., Dimopoulos, G., Fujitani, S., Garnacho-Montero, J., Leone, M., Lipman, J., Ostermann, M., Paiva, J. A., Schouten, J., Sjövall, F., Timsit, J. F., Roberts, J. A., the DIANA study group (2020). Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: the DIANA study. Intensive care medicine, 46(7), 1404–1417. https://doi.org/10.1007/s00134-020-06111-5.Zay Ya, K., Win, P. T. N., Bielicki, J., Lambiris, M., & Fink, G. (2023). Association Between Antimicrobial Stewardship Programs and Antibiotic Use Globally: A Systematic Review and Meta-Analysis. JAMA network open, 6(2), e2253806. https://doi.org/10.1001/jamanetworkopen.2022.53806.Royer, S., DeMerle, K. M., Dickson, R. P., & Prescott, H. C. (2018). Shorter Versus Longer Courses of Antibiotics for Infection in Hospitalized Patients: A Systematic Review and Meta-Analysis. Journal of hospital medicine, 13(5), 336–342. https://doi.org/10.12788/jhm.2905Mo, Y., Oonsivilai, M., Lim, C., Niehus, R., & Cooper, B. S. (2023). Implications of reducing antibiotic treatment duration for antimicrobial resistance in hospital settings: A modelling study and meta-analysis. PLoS medicine, 20(6), e1004013. https://doi.org/10.1371/journal.pmed.1004013.Leone, M., Bechis, C., Baumstarck, K., Lefrant, J. Y., Albanèse, J., Jaber, S., Lepape, A., Constantin, J. M., Papazian, L., Bruder, N., Allaouchiche, B., Bézulier, K., Antonini, F., Textoris, J., Martin, C., & AZUREA Network Investigators (2014). De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial. Intensive care medicine, 40(10), 1399–1408. https://doi.org/10.1007/s00134-014-3411-8.Lakbar, I., De Waele, J.J., Tabah, A. et al. Antimicrobial De-Escalation in the ICU: From Recommendations to Level of Evidence. Adv Ther 37, 3083–3096 (2020). https://doi.org/10.1007/s12325-020-01390-2.Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. 2016. Systematic Review and Meta-analysis of Clinical and Economic Outcomes from the Implementation of Hospital-Based Antimicrobial Stewardship Programs. Antimicrob Agents Chemother 60: https://doi.org/10.1128/aac.00825-16.Madden, G. R., Weinstein, R. A., & Sifri, C. D. (2018). Diagnostic Stewardship for Healthcare-Associated Infections: Opportunities and Challenges to Safely Reduce Test Use. Infection control and hospital epidemiology, 39(2), 214–218. https://doi.org/10.1017/ice.2017.278.Zakhour, J., Haddad, S. F., Kerbage, A., Wertheim, H., Tattevin, P., Voss, A., Ünal, S., Ouedraogo, A. S., Kanj, S. S., & International Society of Antimicrobial Chemotherapy (ISAC) and the Alliance for the Prudent Use of Antibiotics (APUA) (2023). Diagnostic stewardship in infectious diseases: a continuum of antimicrobial stewardship in the fight against antimicrobial resistance. International journal of antimicrobial agents, 62(1), 106816. https://doi.org/10.1016/j.ijantimicag.2023.106816.Vaughn, V. M., Gupta, A., Petty, L. A., Malani, A. N., Osterholzer, D., Patel, P. K., Younas, M., Bernstein, S. J., Burdick, S., Ratz, D., Szymczak, J. E., McLaughlin, E., Czilok, T., Basu, T., Horowitz, J. K., Flanders, S. A., & Gandhi, T. N. (2023). A Statewide Quality Initiative to Reduce Unnecessary Antibiotic Treatment of Asymptomatic Bacteriuria. JAMA internal medicine, 183(9), 933–941. https://doi.org/10.1001/jamainternmed.2023.2749.Fabre, V., Davis, A., Diekema, D. J., Granwehr, B., Hayden, M. K., Lowe, C. F., Pfeiffer, C. D., Sick-Samuels, A. C., Sullivan, K. V., Van Schooneveld, T. C., & Morgan, D. J. (2023). Principles of diagnostic stewardship: A practical guide from the Society for Healthcare Epidemiology of America Diagnostic Stewardship Task Force. Infection control and hospital epidemiology, 44(2), 178–185. https://doi.org/10.1017/ice.2023.5Peri, A. M., Chatfield, M. D., Ling, W., Furuya-Kanamori, L., Harris, P. N. A., & Paterson, D. L. (2024). Rapid diagnostic tests and antimicrobial stewardship programs for the management of bloodstream infection: What is their relative contribution to improving clinical outcomes? A systematic review and network meta-analysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. https://doi.org/10.1093/cid/ciae234Instituto nacional de salud (2024). Informe de evento. Infecciones asociadas a dispositivos. Recuperado junio de 2024, de https://www.ins.gov.co/buscador- eventos/Informesdeevento/IAD%20ABRIL%202024.pdfinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURProaPrograma de optimización de antimicrobianosAntibióticoAntimicrobianoDesescalamientoOptimizaciónAntimicrobialAntibioticsStewardshipDe escalationCaracterización de un programa de optimización de tratamiento antimicrobiano en una institución hospitalaria de IV nivel de Bogotá Colombia entre 2015 2018Characterization of an antimicrobial stewardship program in a level IV hospital institution in Bogotá Colombia between 2015 2018bachelorThesisTrabajo de gradoTrabajo de gradohttp://purl.org/coar/resource_type/c_7a1fEscuela de Medicina y Ciencias de la SaludBogotáORIGINALCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdfCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdfapplication/pdf1225407https://repository.urosario.edu.co/bitstreams/6bc1b3c9-0ae5-4022-b8d8-0fcd87863a4f/downloadbbe9abc9532dd30e3619618ce4490bb2MD51LICENSElicense.txtlicense.txttext/plain1483https://repository.urosario.edu.co/bitstreams/a8113713-cb51-435d-bc14-a51c611429ac/downloadb2825df9f458e9d5d96ee8b7cd74fde6MD52CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-81160https://repository.urosario.edu.co/bitstreams/b52c1439-08ba-4302-b378-98ccff002fd5/download5643bfd9bcf29d560eeec56d584edaa9MD53TEXTCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdf.txtCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdf.txtExtracted texttext/plain101852https://repository.urosario.edu.co/bitstreams/780fb8cf-f7d9-4839-8f16-c7d67e8381be/download29c40fe1258fcf7c3c1fdbd3ecad2b37MD54THUMBNAILCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdf.jpgCaracterización-tratamiento-antimicrobiano-Eduardo_José_Polanía_Guzmán.pdf.jpgGenerated Thumbnailimage/jpeg2536https://repository.urosario.edu.co/bitstreams/4e65bc68-977a-44a7-9fc3-a75d972cf777/download2e84b15a0f0b92c5a203ca521acef75eMD5510336/43229oai:repository.urosario.edu.co:10336/432292024-08-08 13:24:24.778http://creativecommons.org/licenses/by-nc-sa/4.0/Attribution-NonCommercial-ShareAlike 4.0 Internationalhttps://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.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

Publicaciones similares